Business ❯ Employment ❯ Workforce Reduction
Adaptimmune Employees
Adaptimmune retains its two preclinical T cell therapies after selling Tecelra plus two clinical-stage programs in a $55 million deal that shifts commercialization staff to U.S. WorldMeds.
